このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

急性重度一酸化炭素中毒における補助的目標温度管理

2026年11月8日 更新者:Yong Sung Cha、Wonju Severance Christian Hospital

急性重度一酸化炭素中毒における高圧酸素療法と組み合わせた目標温度管理:多施設無作為化対照臨床試験(TTM-COHB試験)

This randomized trial will investigate important neurocognitive clinical outcomes of patients with acute severe carbon monoxide poisoning (ASCOP) randomized to receive either therapeutic hypothermia or normothermia combined with hyperbaric oxygen therapy (HBO).

調査の概要

詳細な説明

CO-poisoned patients are identified by medical history and carboxyhemoglobin (CO-Hb) value >5% (>10% in smokers). Patients presenting with acute CO poisoning will receive one HBO. ASCOP is defined as mental status showing response to painful stimulus or unresponsiveness requiring intubation for airway protection and ventilation support at the emerency department, and persistence of depressed mental status despite the HBO. After HBO treatment, eligible patients who provide consent will be randomly allocated to receive hypothermia, or normothermia treatment administered in a open label fashion except for blinding of outcome assessor.

Outcome measures will be administered at 1 month and 6 months after CO exposure. In addition, we will examine the differences in serum markers and mortality between the hypothermia and normothermia groups.

研究の種類

介入

入学 (実際)

39

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Gangwon-do
      • Wŏnju、Gangwon-do、韓国、26426
        • Wonju Severance Christian Hospital
    • Incheon
      • Incheon、Incheon、韓国、22332
        • Inha University Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

19年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • ≥ 19 years.
  • Patients who received HBO within 24 hours for acute CO poisoning.
  • Patients who meet the definition of ASCOP (Patients incapable verbal obey after HBO).
  • Signed informed consent prior to study entry.

Exclusion Criteria:

  • Cardiac arrest before HBO
  • Previous neurocognitive disorders
  • Life-threatening underlying disease (ex: advanced cancer)
  • Evidence of co-ingestion of sedative or hypnotics confirmed by intravenous flumazenil administration or history taking at the emergency department
  • Absolute contraindication for TH (active severe bleeding and profound shock not controlled by vasoactive drugs)
  • No admission
  • The significant co-ingested drug levels, which are alter the consciousness, is confirmed from the drug analysis lab
  • Pregnancy
  • Burns
  • More than moderate burn or Inhalation burn
  • Burns complicated by other trauma
  • Electrical burn
  • Burns in high risk patients (Patients with chronic underlying diseases (i.e DM, ESRD, liver cirrhosis, etc) which may cause delays or aggravate the wound healing)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Hypothermia group

Hypothermia group is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After therapeutic hypothermia ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.

Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.

アクティブコンパレータ:Normothermia group

For normothermia group, it will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.

Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Main neurocognitive outcome
時間枠:At 6 months after CO poisoning

Global Deterioration Scale [range 1 - 7 (worst score)]

At 6 months after CO poisoning

二次結果の測定

結果測定
メジャーの説明
時間枠
Neurocognitive outcome
時間枠:At 1 month after CO poisoning

Global Deterioration Scale [range 1 - 7 (worst score)]

At 1 month after CO poisoning
Cerebral Performance Category
時間枠:At 1 month and 6 months after CO poisoning

Cerebral Performance Category [range 1 - 5 (worst score)]

At 1 month and 6 months after CO poisoning
modified Rankin scale
時間枠:At 1 month and 6 months after CO poisoning

modified Rankin scale [range 0 - 6 (worst score)]

At 1 month and 6 months after CO poisoning
Glasgow outcome scale
時間枠:At 1 month and 6 months after CO poisoning

Glasgow outcome scale [range 1 (worst score) - 5]

At 1 month and 6 months after CO poisoning
mini-mental status exam
時間枠:At 1 month and 6 months after CO poisoning

mini-mental status exam

At 1 month and 6 months after CO poisoning
Korean version of the Modified Barthel Index
時間枠:At 1 month and 6 months after CO poisoning

Korean version of the Modified Barthel Index

At 1 month and 6 months after CO poisoning
Mortality in intensive care unit
時間枠:Through study completion, an average of 6 months

Number of participants with mortality in intensive care unit

Through study completion, an average of 6 months
Mortality in intensive care unit
時間枠:Through study completion, an average of 6 months

Rate of participants with mortality in intensive care unit

Through study completion, an average of 6 months
In-hospital mortality
時間枠:Through study completion, an average of 6 months

Number of participants with in-hospital mortality

Through study completion, an average of 6 months
In-hospital mortality
時間枠:Through study completion, an average of 6 months

Rate of participants with in-hospital mortality

Through study completion, an average of 6 months
Mortality
時間枠:At 1, 3, and 6 months after CO poisoning

Number of participants with all cause mortality

At 1, 3, and 6 months after CO poisoning
Mortality
時間枠:At 1, 3, and 6 months after CO poisoning

Rate of participants with all cause mortality

At 1, 3, and 6 months after CO poisoning
Length of stay in intensive care unit and hospital
時間枠:Through study completion, an average of 6 months

Length of stay in intensive care unit and hospital

Through study completion, an average of 6 months
Pneumonia
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Pneumonia
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Shock
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Shock
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Bradycardia
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with dropped heart rate indicated drug or interventions

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Bradycardia
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with dropped heart rate indicated drug or interventions

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypokalemia
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with serum K concentration <3.0 - 2.5 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypokalemia
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with serum K concentration <3.0 - 2.5 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperkalemia
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with serum K concentration >6.0 - 7.0 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperkalemia
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with serum K concentration >6.0 - 7.0 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperglycemia
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperglycemia
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypophosphatemia
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypophosphatemia
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypomagnesemia
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with serum magnesium <0.9 - 0.7 mg/dL

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypomagnesemia
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with serum magnesium <0.9 - 0.7 mg/dL

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged prothrombin Time International Normalized Ratio
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged prothrombin Time International Normalized Ratio
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged activated partial thromboplastin time
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged activated partial thromboplastin time
時間枠:During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
S100ß (serum)
時間枠:Within 14 days after CO exposure

Concentration of S100ß (serum)

Within 14 days after CO exposure
Neuronal specific enolase (serum)
時間枠:Within 14 days after CO exposure

Concentration of neuronal specific enolase (serum)

Within 14 days after CO exposure
Brain magnetic resonance image (MRI)
時間枠:Within 14 days after CO exposure

Number of participants with brain injury in brain MRI

Within 14 days after CO exposure
Brain magnetic resonance image (MRI)
時間枠:Within 14 days after CO exposure

Rate of participants with brain injury in brain MRI

Within 14 days after CO exposure

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Yong Sung Cha, MD、Wonju Severance Christian Hospital

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年10月25日

一次修了 (実際)

2025年11月7日

研究の完了 (実際)

2025年11月7日

試験登録日

最初に提出

2021年7月1日

QC基準を満たした最初の提出物

2021年7月13日

最初の投稿 (実際)

2021年7月26日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月8日

最終確認日

2025年6月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • TTM-COHB trial
  • CR220011 (その他の識別子:Wonju Severance Christian Hospital)
  • 2021-04-043 (その他の識別子:Inha University Hospital)

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する